Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression.
Journal of Psychopharmacology April 24, 2026 Marco Colizzi, Elisa Morandin, Veronica Croccia et al.
Interleukin-6 (IL-6) has been implicated as a potential predictor of ketamine response in treatment-resistant depression (TRD). Esketamine, the S-enantiomer of ketamine, produces rapid antidepressant effects and offers improved safety and intranasal administration. To examine whether baseline IL-6 predicts treatment response to esketamine in individuals with TRD. Fourteen adults with TRD...
DOI: 10.1177/02698811261443676 (opens in new tab)
Full text (opens in new tab)
Esketamine
Treatment-resistant depression
Biological predictors
Glutamatergic system
+4